Federal Marijuana ReschedulingThe Potential Impact on DOT and Non-DOT Drug and Alcohol Programs
Where things currently standIn April 2026, the U.S. Department of Justice moved two narrow categories of marijuana from Schedule I to Schedule III: FDA-approved drug products containing marijuana, and marijuana handled under a qualifying state medical marijuana license. All other marijuana — including recreational use and medical use outside a licensed state program — remains Schedule I.
A separate DEA proceeding on moving marijuana as a whole to Schedule III held hearings from June 29 through July 15, 2026. Post-hearing briefs were due August 17, 2026. The Administrative Law Judge has not yet issued a recommendation, and no final rule has been published.
Nothing in 49 CFR Part 40 has changed. Marijuana remains on the DOT testing panel for all safety-sensitive employees, and a state medical marijuana card is still not a valid medical explanation for a positive result.
Why we are askingDOT’s authority to test for marijuana runs through the HHS Mandatory Guidelines, which authorize testing for Schedule I and Schedule II substances. The National Transportation Safety Board has cautioned the DEA that a full move to Schedule III would, absent an explicit carve-out or a technical amendment to those Guidelines, cut off marijuana testing under Part 40. That gap has not been closed.
Your responses will help NCMS understand where operators stand, shape the position we take, and focus the guidance and support we develop for you.
New NCMS web portal - In Development!Since April, we have been building a next-generation monitoring platform designed with operator needs in mind.
Planned capabilities include:
Official launch is expected in Spring 2027, which means there is still time for operator input to shape what gets built. We would like to walk you through what exists today and capture your wish-list items while changes are still easy to make.